The OT-I mouse T-cell receptor (TCR) is thought to perfectly discriminate between lower-affinity self- and higher-affinity foreign antigen-MHC complexes. This study shows OT-I TCR to exhibit imperfect ...
AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...
Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...
Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback